Cohen, S <br/><br/>
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.  [electronic resource] 

 -  Arthritis and rheumatism  Nov 1999 
 - 2309-18 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0004-3591 
<br/><br/><label>Standard No.: </label>10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adrenal Cortex Hormones--adverse effects<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Analysis of Variance<br/>Biomarkers<br/>Bone Resorption--chemically induced<br/>Calcium Channel Blockers--adverse effects<br/>Demography<br/>Double-Blind Method<br/>Etidronic Acid--adverse effects<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Risedronic Acid